Modality
mRNA
MOA
SHP2i
Target
TROP-2
Pathway
Innate Imm
MDD
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
Phase 2Current
NCT03117480
2,625 pts·MDD
2021-01→TBD·Active
2,625 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2021
P2/3
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03117480 | Phase 2/3 | MDD | Active | 2625 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα |